Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Cerus Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Eversense 365, all published on March 3, 2026.
1 verified story tracked
Last mentioned: Mar 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Cerus Corporation is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Eversense 365, all published on March 3, 2026. Each carries 11 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Eversense 365. Shared-story counts are live from our verified record — not editorial picks.
UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
